Lifestyle changes for low-risk myelodysplastic syndrome
Part of Blood & lymphatic clinical trials.
This study looks at whether healthy lifestyle changes (such as diet and exercise) can help people with low-risk Myelodysplastic Syndrome (MDS), a condition where the bone marrow doesn't produce enough healthy blood cells. It may improve anemia and overall well-being.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a confirmed diagnosis of low-risk or intermediate-risk Myelodysplastic Syndrome (MDS), a blood disorder where the bone marrow doesn't make enough healthy blood cells.
- Your hemoglobin levels are below 11 g/dL, meaning you have anemia (low red blood cells).
- You have not needed frequent blood transfusions — no more than 2 transfusions in the 16 weeks before joining the study.
- You are generally able to care for yourself (ECOG score of 2 or less).
- Your body mass index (BMI) is at least 20 and you have no medical condition (like diabetes or a mental health issue) that would prevent you from following lifestyle changes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at special stem cells in the blood or bone marrow of people with myelodysplastic syndromes (MDS). It aims to better predict how the disease might progress and help guide treatment decisions.
This study tests a new drug, momelotinib, for people with a low-risk form of myelodysplastic syndrome (MDS) who need red blood cell transfusions and have already tried one other treatment (like ESAs or luspatercept). The goal is to see if momelotinib can help reduce transfusion needs.
This study uses repeated blood samples to watch how genetic changes in your blood evolve in lower-risk myelodysplastic syndrome (MDS). It may help doctors understand what mutation changes mean over time for people not on strong cancer-fighting treatments.
This study tests a new therapy called MNV-201 for people with low-risk myelodysplastic syndromes (MDS) who have anemia and need regular blood transfusions. The goal is to see if this treatment can help reduce or stop the need for transfusions.
This study carefully evaluates people with myelodysplastic syndromes (MDS) and closely related blood disorders using detailed medical, blood, and bone marrow testing. The goal is to better understand these conditions and how they progress, which may help guide future care.
This study tests a new drug called elritercept for people with myelodysplastic syndromes (MDS) who have low blood counts and need regular blood transfusions. The drug aims to boost red blood cell production and reduce or eliminate the need for transfusions, which can improve energy and quality of life.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.